Hypersensitivity pneumonitis caused by triglycidyl isocyanurate

Santiago Quirce(Hospital Universitario La Paz), J. Sastre(Centro de Investigación Biomédica en Red de Enfermedades Respiratorias), G Renedo(Hospital Universitario Fundación Jiménez Díaz), Jerónimo Carnés(Hospital Universitario Fundación Jiménez Díaz), M Fernández-Nieto(Hospital Universitario Fundación Jiménez Díaz), Miguel Górgolas(Hospital Universitario Fundación Jiménez Díaz)
Allergy
September 7, 2004
10.1111/j.1398-9995.2004.00506.x
Cited by 12

Related Papers

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma
|Allergy|2020|406
EAACI Biologicals Guidelines—Recommendations for severe asthma
|Allergy|2020|275
Severe eosinophilic asthma: a roadmap to consensus
|European Respiratory Journal|2017|187
Current evidence and future research needs for FeNO measurement in respiratory diseases
|Respiratory Medicine|2014|183
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain
|PLoS ONE|2018|179